Deutsche Bank upgraded West Pharmaceutical Services (NYSE:WST) to Buy from Hold on Friday, even after the contract drug manufacturer witnessed a ~38% drop in the previous session following a ...

The bank on Thursday ditched its closely watched cost target for 2025, saying it wanted to make investments in business. It now aims for a cost-to-income ratio of below 65%, compared with previous ...

Deutsche Bank upgraded West Pharmaceutical (WST) to Buy from Hold with a price target of $250, down from $275. The company’s Q4 results and a ...

Deutsche Bank lowered the firm’s price target on TransUnion (TRU) to $115 from $118 and keeps a Buy rating on the shares following the “solid” ...

Investing.com -- The dot com bubble of the late 1990s was a period of extraordinary growth and speculation in technology ...

Deutsche Bank has a wake up call for analysts who denied Trump would deliver on tax rhetoric—but UBS is questioning how ...

Deutsche Bank reported solid Q4 results with €7.2 billion in revenue, driven by a 30% YoY jump in the investment bank. Read more about DB stock here.

Deutsche Bank’s shift to Google Cloud powers up its AI capabilities, optimising operations and slashing process times ...

Deutsche Bank AG was fined €10 million ($10.3 million) by Spain’s securities regulator CNMV for selling derivatives to ...

Chinese stock gauges will top prior highs in the medium term as the world wakes up to the competitiveness of its companies, according to Deutsche Bank.

Deutsche Bank Aktiengesellschaft's Q4 results showed an 8.6% revenue increase but a 17% drop in pre-tax profit. Click here to find out why DB stock is a Buy.

Deutsche Bank Aktiengesellschaft assumed coverage on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a ...